Epidemiology of BK Virus in Renal Allograft Recipients: Independent Risk Factors for BK Virus Replication

Dadhania, Darshana; Snopkowski, Catherine; Ding, Ruchuang; Muthukumar, Thangamani; Chang, Christina; Aull, Meredith J.; Lee, Jun; Sharma, Vijay Kumar; Kapur, Sandip; Suthanthiran, Manikkam

doi:10.1097/tp.0b013e31817c6447

Cited by 114 publications

(102 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PyVAN affects up to 10% of kidney transplant recipients, and the rate of renal allograft loss varies from 10% to 80% (41,42). About 30%-50% of kidney transplant recipients with high-level viruria progress to BKV viremia and PyVAN (40).…”

Section: Bk Polyoma Virus Infectionmentioning

confidence: 99%

Common Infections in Kidney Transplant Recipients

Karuthu¹,

Blumberg

2012

Clinical Journal of the American Society of Nephrology

214

148

View full text Add to dashboard Cite

SummaryInfections are a major cause of morbidity and mortality in kidney transplant recipients. To some extent, these may be preventable. Careful pretransplant screening, immunization, and post-transplant prophylactic antimicrobials may all reduce the risk for post-transplant infection. However, because transplant recipients may not manifest typical signs and symptoms of infection, diagnoses may be confounded. Furthermore, treatment regimens may be complicated by drug interactions and the need to maintain immunosuppression to avoid allograft rejection. This article reviews common post-transplant infections, including prophylactic, diagnostic, and treatment strategies, providing guidance regarding care of kidney transplant patients with infection.

show abstract

Section: Bk Polyoma Virus Infectionmentioning

confidence: 99%

Common Infections in Kidney Transplant Recipients

Karuthu¹,

Blumberg

2012

Clinical Journal of the American Society of Nephrology

214

148

View full text Add to dashboard Cite

show abstract

“…Studies report various agents such as antirejection treatment regimens with pulse steroid, 11 steroid use and antithymocyte globulin induction therapy, 12 high level of tacrolimus, 13,14 and mycophenolate mofetil, 14,15, as being responsible for the emergence of BK viremia and viruria. In our study, no statistically significant association was found between the type of immunosuppressant and BK virus positivity.…”

Section: Discussionmentioning

confidence: 99%

Untitled

Avkan-Oguz²,

Ünek³

et al. 2014

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Because of the controversy regarding the effects of BK virus on non-renal solid-organ transplant, we detected the BK virus via different methods and its effect on clinical findings, liver and kidney functions, and graft dysfunction in liver transplant recipients. Materials and Methods: This prospective cohort study comprised patients over the age of 18, who consecutively received liver transplant from January 1 to December 31, 2011. The patients were examined once, every 2 weeks, for the first 3 months after transplant. Clinical findings were evaluated on each examination; blood and urine samples were collected, BK virus DNA was assessed with real-time polymerase chain reaction, and the presence of decoy cells (which are epithelial cells with large nuclei and large basophilic inclusions) in the urine was investigated. Patients were followed-up for 1 year to see if rejection occurred. Results: Five of 39 patients (12.8%) showed BK viremia; 11 patients (28.2%) showed BK viruria, and 13 (33.3%) showed decoy cells. No statistically significant differences were found between BK virus positive and negative groups, respecting demographic variables, kidney and liver functions, and graft survival. BK virus DNA positivity in blood was the standard, while decoy cell assessment in urine and BK virus polymerase chain reaction test sensitivity in urine was 40%. Conclusions: No matter the method used to detect BK virus in the urine, the negativity of the tests is more valuable than their positivity. Although no statistically significant difference was found between the groups, we concluded that BK virus is a factor that should be considered when unexplained deterioration in kidney and liver function tests is observed in liver transplant recipients. Prospective studies with larger numbers of patients are warranted.

show abstract

“…BKV associated nephropathy affects 1-10% of renal transplant recipients and linked to the strength of the immunosuppression. Higher incidence of BK viremia is related to a higher dose of rabbit ATG [72][73][74][75].…”

Section: Bk Virus (Bkv)mentioning

confidence: 99%

Low Dose Rabbit Anti-Thymocyte Globulin as an Induction immunosuppression in High-Risk Renal Transplant Recipients

Halawa¹

2017

UNOAJ

View full text Add to dashboard Cite

High immunologic risk recipients pose a major challenge in transplantation. It is associated with early acute rejection post-transplantation and leads to decrease patient and graft survival. The need for effective immunosuppression early post-transplantation has resulted in emerging of induction protocols. Biologic agents used for induction are classified to monoclonal and polyclonal which are either depletive or non-depletive antibody therapies. Choosing the best agent and optimal dose remains a controversial issue and depends on many factors including the proper assessment of the immunologic risk, efficacy and safety of the used agent. There is no consensus for the optimal agent used as induction immunosuppression in kidney transplantation. rATG use is associated with decreased incidence of delayed graft function and acute rejection episodes.

show abstract

Epidemiology of BK Virus in Renal Allograft Recipients: Independent Risk Factors for BK Virus Replication

Cited by 114 publications

References 29 publications

Common Infections in Kidney Transplant Recipients

Common Infections in Kidney Transplant Recipients

Untitled

Low Dose Rabbit Anti-Thymocyte Globulin as an Induction immunosuppression in High-Risk Renal Transplant Recipients

Contact Info

Product

Resources

About